Skip to main content

Kybella FDA Approval History

FDA Approved: Yes (First approved April 29, 2015)
Brand name: Kybella
Generic name: deoxycholic acid
Dosage form: Injection
Previous Name: ATX-101
Company: Allergan plc
Treatment for: Submental Fullness

Kybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin).

Development timeline for Kybella

DateArticle
Apr 29, 2015Approval FDA Approves Kybella (deoxycholic acid) to Treat Submental Fullness, or 'Double Chin'
Mar  9, 2015Kythera Biopharmaceuticals Announces FDA Advisory Committee Unanimously Recommends to Approve ATX-101

See also

Kybella (deoxycholic acid) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer